Journal article
Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
Cancer management and research, Vol.7, pp.253-264
12 Aug 2015
PMCID: PMC4542411
PMID: 26316817
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.
Metrics
6 Record Views
Details
- Title
- Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
- Creators
- Sergey V Karakashev - Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USAMauricio J Reginato - Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA
- Publication Details
- Cancer management and research, Vol.7, pp.253-264
- Publisher
- Dove Medical Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Biochemistry and Molecular Biology
- Identifiers
- 991014877828704721
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Web of Science research areas
- Oncology